𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Optimal Bayesian-feasible dose escalation for cancer phase I trials

✍ Scribed by S. Zacks; A. Rogatko; J. Babb

Book ID
104302802
Publisher
Elsevier Science
Year
1998
Tongue
English
Weight
301 KB
Volume
38
Category
Article
ISSN
0167-7152

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cancer phase I clinical trials: efficien
Cancer phase I clinical trials: efficient dose escalation with overdose control
✍ James Babb; AndrΓ© Rogatko; Shelemyahu Zacks πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 172 KB πŸ‘ 1 views

We describe an adaptive dose escalation scheme for use in cancer phase I clinical trials. The method is fully adaptive, makes use of all the information available at the time of each dose assignment, and directly addresses the ethical need to control the probability of overdosing. It is designed to

Optimal multi-stage designs for a phase
Optimal multi-stage designs for a phase II trial that permits one dose escalation
✍ John J. Hanfelt πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 2 views

Simon's optimal two-stage design is widely used to conduct single-dose phase II clinical trials. We extend this basic methodology to the situation where the researcher desires to test an experimental drug for activity at a low dose level, but is willing to increase the dose part-way through the tria